Biblio

Add Citation
Export 17 results:
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Aarsland, Dag  [Clear All Filters]
2010
Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, et al. Gray matter correlations of cognition in incident Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2010.
Olin JT, Aarsland D, Meng X. Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: Effects on Activities of Daily Living. Dementia and geriatric cognitive disorders. 2010;29(6):510-5.
Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, et al. CSF amyloid-{beta} and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. Journal of neurology, neurosurgery, and psychiatry. 2010.
Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord. 2010;25(6):687-8.
Schmitt FA, Aarsland D, Brønnick KS, Meng X, Tekin S, Olin JT. Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items. American journal of Alzheimer's disease and other dementias. 2010.
2009
Ballard C, Jones EL, Londos E, Minthon L, Francis P, Aarsland D. alpha-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. International psychogeriatrics / IPA. 2009:1-7.
Kurz M, Dekomien G, Nilsen O, Larsen J, Aarsland D, Alves G. APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study. Journal of geriatric psychiatry and neurology. 2009.
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet neurology. 2009.
Dalaker TO, Larsen JP, Dwyer MG, Aarsland D, Beyer MK, Alves G, et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage. 2009.
2008
Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008;23(4):484-500.
2007
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-707; quiz 1837.
Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatr. 2007;78(3):254-9.
Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061-8.
Kurz M, Schlitter A, Klenk Y, Mueller T, Larsen J, Aarsland D, et al. FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study. Journal of geriatric psychiatry and neurology. 2007;20(2):89-92.
Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314-24.
Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology. 2007;69(8):747-54.
2006
Alves G, Larsen J, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord. 2006;21(8):1123-30.